IQVIA Holdings Inc.
IQV · NYSE
Analyst ratings
strong_buy · 13 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| July 13, 2026 | Mizuho | Maintains | Outperform | $230.00 |
| July 1, 2026 | Baird | Maintains | Outperform | $249.00 |
| June 17, 2026 | Morgan Stanley | Downgrades | Equal-Weight | $200.00 |
| April 8, 2026 | Evercore ISI Group | Maintains | Outperform | $185.00 |
| March 9, 2026 | TD Cowen | Upgrades | Buy | $213.00 |
| March 6, 2026 | Barclays | Upgrades | Overweight | $210.00 |
| February 19, 2026 | Truist Securities | Maintains | Buy | $245.00 |
| February 6, 2026 | JP Morgan | Maintains | Overweight | $225.00 |
| February 6, 2026 | Citigroup | Maintains | Neutral | $200.00 |
| February 6, 2026 | UBS | Maintains | Buy | $240.00 |
| February 6, 2026 | Jefferies | Maintains | Buy | $255.00 |
| February 6, 2026 | Stifel | Maintains | Buy | $220.00 |
| February 6, 2026 | Barclays | Maintains | Equal-Weight | $210.00 |
| January 22, 2026 | TD Cowen | Maintains | Hold | $245.00 |
| January 8, 2026 | Truist Securities | Maintains | Buy | $290.00 |
| January 8, 2026 | UBS | Maintains | Buy | $280.00 |
| December 2, 2025 | Morgan Stanley | Maintains | Overweight | $265.00 |
| November 3, 2025 | TD Cowen | Downgrades | Hold | $215.00 |
| October 29, 2025 | Citigroup | Maintains | Neutral | $230.00 |
| October 29, 2025 | UBS | Maintains | Buy | $250.00 |
| October 29, 2025 | Stifel | Maintains | Buy | $254.00 |
| October 29, 2025 | Truist Securities | Reiterates | Buy | $265.00 |
| October 29, 2025 | JP Morgan | Maintains | Overweight | $255.00 |
| October 29, 2025 | Baird | Upgrades | Outperform | $258.00 |
| October 9, 2025 | HSBC | Upgrades | Buy | $235.00 |
| October 8, 2025 | Evercore ISI Group | Maintains | Outperform | $240.00 |
| October 2, 2025 | Barclays | Maintains | Equal-Weight | $200.00 |
| September 9, 2025 | Jefferies | Upgrades | Buy | $225.00 |
AI-driven transformation of clinical trials and IQVIA's competitive positioning
IQVIA is regarded as a key player in the AI-driven transformation of the clinical trials market, which is attracting substantial investment. Multiple analysts have raised price targets, with Baird designating the stock a 'Fresh Pick' and maintaining its Outperform rating, reflecting confidence in the company's ability to capitalize on AI-integrated solutions.
Despite enthusiasm around AI, IQVIA's stock remains down 9.2% year-to-date and is trading significantly below its 52-week high, suggesting the market is not fully convinced that AI tailwinds will translate into near-term financial gains or a fundamental re-rating of the business.
Valuation and earnings growth sustainability amid leverage concerns
The most widely followed analyst narrative pins IQVIA's fair value near the mid-$220s, implying the stock is undervalued by approximately 8.9% at current levels. Analysts project earnings to reach $2.0–$2.5 billion by 2029, supported by measured revenue growth, firmer margins, and a valuation multiple consistent with quality compounders.
IQVIA faces persistent CRO pricing pressure and carries high leverage, meaning that any margin weakness or costlier debt refinancing could rapidly erode the undervaluation thesis. Longer-term 3- and 5-year total shareholder returns remain in decline, casting doubt on the durability of recent momentum.
Morgan Stanley downgrade versus broad analyst consensus upgrade cycle
A broad cohort of analysts—including Leerink Partners, Baird, Mizuho, Evercore ISI, HSBC, and Argus—have raised their price targets for IQVIA in mid-2026, with a mean consensus of BUY among 22 analysts and an average target of $232, implying meaningful upside from current trading levels.
Morgan Stanley bucked the consensus in June 2026 by downgrading IQVIA from Overweight to Equalweight and cutting its price target from $225 to $200, triggering a notable share price decline. This divergence highlights genuine disagreement about IQVIA's near-term risk-reward profile relative to peers.